
Verification of COVID-19 vaccine animal trials skipping and reasons behind it.
-
Animal trials were not skipped for COVID-19 vaccines. • 0:15
-
Need for full information beyond quick answers. • 0:31
-
Regulators determine adequacy of trials. • 1:04
-
Importance of context in evaluating trial adequacy. • 1:12
-
Animal deaths did not lead to skipping trials. • 1:59
-
Discussion on vaccine trials and animal deaths in Texas Senate hearing. • 2:28
-
Fact checkers found no evidence of skipping trials due to animal deaths. • 2:51
Investigating the progression of COVID-19 vaccine research from pre-clinical to clinical trials.
-
Pfizer announced pre-clinical studies of mRNA vaccine candidate in September 2020. • 3:13
-
Reference to a pre-print paper on spike mRNA vaccine’s immunogenicity in non-human primates. • 3:45
-
The pre-print paper is still awaiting peer review, causing uncertainty. • 4:21
-
A study by Nimrat Khidra in June 2021 detailed the journey from pre-clinical to clinical trials for the Pfizer vaccine. • 4:40
-
Sequential testing of four vaccine candidates in animal species like macaques and mice. • 5:06
-
Importance of using closely related species like macaques for vaccine research due to similar immune responses. • 5:50
-
Discussion on the use of animals in vaccine research within a one-year timeframe. • 6:01
COVID-19 vaccine development process and importance of parallel animal studies.
-
Regulators allowed pre-clinical studies to run parallel to clinical studies to save time. • 6:08
-
Ongoing animal studies in parallel can help anticipate future issues like the need for boosters. • 6:39
-
Phase 1 and 2 clinical trials with healthy participants started in April 2020 in Germany. • 7:23
-
Animal trials were conducted on rhesus macaques with promising immune responses to the vaccine. • 8:09
-
Challenge studies on macaques post-vaccination showed good immune response against new viral exposure. • 9:03
Evaluation of COVID-19 vaccine safety in macaques lacked post-challenge data and animal model studies.
-
Study split macaques for intranasal and intratracheal vaccine routes. • 9:29
-
Autopsies conducted on macaques after challenge study at day 44. • 9:53
-
Limited data on immune responses post-second vaccine dose at peak antibody levels. • 10:20
-
Post-challenge necroscopy within two weeks provided some safety insights. • 11:27
-
Call for more animal model studies and parallel research by regulators. • 12:02
-
Importance of autopsy data in understanding vaccine effects on patients. • 12:17
-
Critical review of limited autopsies on COVID-19 vaccinated patients. • 12:26
Evaluation of animal trials for COVID-19 vaccines and the importance of full disclosure in fact-checking.
-
Importance of parallel animal studies to understand vaccine impact on new variants like omicron. • 12:48
-
Questioning the adequacy of animal trials for COVID-19 vaccines in terms of safety and long-term impact on humans. • 13:45
-
Lack of evidence for comprehensive parallel animal studies to assess vaccine outcomes with new variants. • 13:52
-
Emphasis on presenting the whole truth in fact-checking to maintain trust in science. • 14:15
-
Encouragement to explore independent information on COVID-19 through provided resources. • 14:29